Orgenesis (ORGS) News Today $1.30 -0.10 (-7.14%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analyzing Zentalis Pharmaceuticals (NASDAQ:ZNTL) & Orgenesis (NASDAQ:ORGS)December 19 at 3:27 AM | americanbankingnews.comComparing BridgeBio Pharma (NASDAQ:BBIO) and Orgenesis (NASDAQ:ORGS)December 18 at 1:50 AM | americanbankingnews.comOrgenesis Inc. Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comOrgenesis Provides Third Quarter 2024 Business UpdateNovember 13, 2024 | markets.businessinsider.comOrgenesis Expands Board with Three New AppointmentsNovember 3, 2024 | markets.businessinsider.comOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comOrgenesis Inc. (NASDAQ:ORGS) Short Interest Down 85.1% in SeptemberOrgenesis Inc. (NASDAQ:ORGS - Get Free Report) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 56,300 shares, a decrease of 85.1% from the September 15th total of 377,400 shares. Approximately 1.3% of the company's shares are short sold. Based on an average trading volume of 22,900 shares, the short-interest ratio is currently 2.5 days.October 10, 2024 | marketbeat.comOrgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com45O.SG,0P0001J8IU,0 (45O.SG)September 24, 2024 | au.finance.yahoo.comWhy Orgenesis (ORGS) Stock Is Down 23% TodaySeptember 24, 2024 | msn.comOrgenesis Inc.: Orgenesis Announces Reverse Stock SplitSeptember 23, 2024 | finanznachrichten.deOrgenesis Approves 1-for-10 Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comOrgenesis Announces Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comOrgenesis Announces Real-World Data Of ORG-101 CAR-T Therapy For CD19+ Acute Lymphoblastic LeukemiaAugust 29, 2024 | markets.businessinsider.comOrgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic LeukemiaAugust 29, 2024 | globenewswire.comORGS Company Profile & Executives - Orgenesis Inc. - Wall Street JournalAugust 27, 2024 | wsj.comOrgenesis forms joint venture with Harley Street HealthcareAugust 16, 2024 | investing.comOrgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative GloballyAugust 14, 2024 | globenewswire.comWhy Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving PremarketAugust 13, 2024 | msn.comORGS Stock Earnings: Orgenesis Reported Results for Q2 2024August 9, 2024 | msn.comOrgenesis Provides Second Quarter 2024 Business UpdateAugust 8, 2024 | markets.businessinsider.comORGS Stock Earnings: Orgenesis Reported Results for Q4 2023May 31, 2024 | investorplace.comORGS Stock Earnings: Orgenesis Misses Revenue for Q1 2024May 21, 2024 | investorplace.comOrgenesis Provides Business Update for the First Quarter of 2024May 21, 2024 | globenewswire.comOrgenesis secures $2.3 million investment and strategic partnershipApril 17, 2024 | investing.comOrgenesis Inc.: Orgenesis Provides Year End Business UpdateApril 17, 2024 | finanznachrichten.deOrgenesis Provides Year End Business UpdateApril 15, 2024 | globenewswire.comGermfree partners with Orgenesis to enhance CGT productionApril 11, 2024 | investing.comGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityApril 10, 2024 | globenewswire.comVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceMarch 18, 2024 | globenewswire.comOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesMarch 13, 2024 | globenewswire.comOrgenesis Inc. Announces $2.3 Million Private PlacementMarch 4, 2024 | globenewswire.comOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingFebruary 29, 2024 | globenewswire.comOrgenesis Inc. (ORGS)February 23, 2024 | finance.yahoo.comOrgenesis Inc ORGSFebruary 22, 2024 | morningstar.comEXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To ClinicJanuary 31, 2024 | msn.comOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicJanuary 31, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo FinanceJanuary 8, 2024 | finance.yahoo.comAnalysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven SoonNovember 22, 2023 | finance.yahoo.comOrgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023November 15, 2023 | finanznachrichten.deOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNovember 14, 2023 | finance.yahoo.comOrgenesis Provides Business Update for the Third Quarter of 2023November 13, 2023 | finance.yahoo.comOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNovember 8, 2023 | finance.yahoo.com6 Secrets Of Organizations That Successfully Adapt To ChangeNovember 5, 2023 | forbes.comOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingNovember 2, 2023 | finance.yahoo.comOrgenesis Inc.: Orgenesis Announces Withdrawal of Proposed Public OfferingOctober 31, 2023 | finanznachrichten.deOrgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Proposed Underwritten Public OfferingOctober 30, 2023 | finance.yahoo.comCGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesSeptember 21, 2023 | stockhouse.com Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW ORGS Media Mentions By Week ORGS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORGS News Sentiment▼0.000.60▲Average Medical News Sentiment ORGS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORGS Articles This Week▼20▲ORGS Articles Average Week Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Carisma Therapeutics News MIRA Pharmaceuticals News Unity Biotechnology News Pieris Pharmaceuticals News Cadrenal Therapeutics News MEI Pharma News Synlogic News Aprea Therapeutics News BioLineRx News Cyclo Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORGS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
